Table 1.
Association between CDK5 expression and the clinicopathological characteristics (logistic regression) of gliomas in TCGA and GSE16011
| Clinical characteristics | TCGA | GSE16011 | ||||
|---|---|---|---|---|---|---|
| Total (N) | Odds ratio (95%CI) | P-value | Total (N) | Odds ratio (95%CI) | P-value | |
| Age (≥52 vs. <52) | 670 (263 vs. 407) | 2.47 (1.80-3.41) | <0.001 | 276 (133 vs. 143) | 1.85 (1.15-2.99) | 0.0117 |
| Sex (male vs. female) | 670 (386 vs. 284) | 0.822 (0.605-1.12) | 0.211 | 276 (184 vs. 92) | 1 (0.606-1.65) | 1 |
| Vital status (dead vs. alive) | 670 (220 vs. 450) | 2.36 (1.69-3.29) | <0.001 | 264 (240 vs. 24) | 2.64 (1.10-7.04) | 0.0378 |
| Grade (IV vs. I+II+III) | 670 (161 vs. 509) | 6.53 (4.28-10.2) | <0.001 | 276 (159 vs. 117) | 1.88 (1.16-3.05) | 0.011 |
| Histological type | ||||||
| (GBM vs. pilocytic astrocytoma) | 166 (159 vs. 8) | 64.3 (1.03e-06-NA*) | 0.984 | |||
| (GBM vs. astrocytoma) | 352 (160 vs. 192) | 9.87 (6.09-16.4) | <0.001 | 188 (159 vs. 29) | 1.46 (1.10-1.98) | 0.0111 |
| (GBM vs. oligoastrocytoma) | 288 (160 vs. 128) | 4.65 (2.83-7.74) | <0.001 | 187 (159 vs. 28) | 0.988 (0.439-2.22) | 0.976 |
| (GBM vs. oligodendroglioma) | 350 (160 vs. 190) | 5.85 (3.71-9.38) | <0.001 | 211 (159 vs. 52) | 1.10 (0.804-1.51) | 0.549 |
| Tumor status (with tumor vs. tumor free) | 591 (400 vs. 191) | 1.72 (1.21-2.44) | 0.002 | |||
| IDH1 mutation (yes vs. no) | 125 (91 vs. 34) | 0.428 (0.185-0.954) | 0.0414 | 226 (83 vs. 143) | 0.963 (0.560-1.65) | 0.890 |
| KPS (<80 vs. ≥80) | 412 (71 vs. 341) | 2.82 (1.65-4.99) | <0.001 | 265 (82 vs. 183) | 0.922 (0.546-1.55) | 0.759 |
| Ethnicity (Hispanic or Latino vs. not Hispanic or Latino) | 609 (34 vs. 575) | 0.342 (0.149-0.720) | 0.007 | |||
| Family history of cancer (yes vs. no) | 338 (132 vs. 206) | 1.35 (0.871-2.09) | 0.181 | |||
*NA, not available.